Post-earnings recap
Reported
Thu, Jul 28, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock increased by 1.09%, possibly due to overall market conditions or investor sentiment. The lack of revenue data and guidance may leave investors cautious about the company's near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.03 | N/A | -25.31% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced during the quarter. They emphasized their commitment to long-term objectives without providing specific guidance.
Management did not provide specific guidance for future quarters.
The company remains focused on its long-term strategic goals despite the current challenges.